Kivu Bioscience president and COO Mohit Trikha (L) and Novo Holdings partner, venture investments Daniel O’Connell
October 28, 2024 08:00 AM EDTUpdated 09:47 AM
Financing
Startups

Synaf­fix, in­dus­try's ADC part­ner of choice, spins out a start­up pipeline

Kyle LaHucik

Senior Reporter

The Dutch biotech Synaf­fix has long been one of the top part­ners for bio­phar­ma com­pa­nies work­ing in an­ti­body-drug con­ju­gates. Now the com­pa­ny is spin­ning out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times